917068.fig.002
Figure 2: Palivizumab indications across seasons. Indications are subcategorized into chronic lung disease (BPD/CLD, ), premature ( ), hemodynamically significant congenital heart disease (HSCHD, ), and “other” ( ). The “other” group comprises infants with serious underlying medical disorders.